Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy (CHLORODEX)

25. Juni 2026 aktualisiert von: CMC Ambroise Paré

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial

Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.

Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.

Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.

This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.

Studienübersicht

Detaillierte Beschreibung

This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.

Participants will be randomly allocated into two groups:

  • Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
  • Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.

To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.

The infusion will start approximately 10-15 minutes before the spinal punction.

In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.

Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.

Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.

No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.

Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.

Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).

Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.

The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Île-de-France Region
      • Paris, Île-de-France Region, Frankreich, 75016
        • Clinique Drouot Rémusat
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
  • Signed written informed consent form,
  • Affiliation to a social security system,
  • Negative pregnancy test on the day of procedure for non-menopausal patients.

Exclusion Criteria:

  • Contraindications to spinal anesthesia with intrathecal chloroprocaine
  • History of diabetes,
  • Pre-existing peripheral neuropathy,
  • American Society of Anesthesiologists (ASA) physical status IV,
  • Contraindication to dexamethasone,
  • Hypersensitivity of any drug used in this study,
  • Long-term oral corticosteroid therapy,
  • Chronic opioid use,
  • Chronic pain syndromes,
  • Contraindications to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Ketoprofen, Celecoxib)
  • Need for a peripheral nerve block in addition to spinal anesthesia (e.g. knee ligamentoplasty),
  • Mental or linguistic inability to understand the study,
  • Patients under legal protection (guardianship, curatorship or safeguard of justice),
  • Patients currently included or planning to be included in another interventional study,
  • Pregnant or breastfeeding women,
  • Women of childbearing potential not using effective contraception.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: CHLORO
Normal saline solution IV infusion
IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
Spinal anesthesia with chloroprocaine 40 mg
Experimental: CHLORODEX
Dexamethasone IV infusion
Spinal anesthesia with chloroprocaine 40 mg
IV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to regression of sensory block by two dermatomes (pin-prick test)
Zeitfenster: Up to 2 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Up to 2 hours following spinal anesthesia

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to complete resolution of motor block
Zeitfenster: Up to 8 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).
Up to 8 hours following spinal anesthesia
Time to regression of sensory block by four dermatomes (pin-prick test)
Zeitfenster: Up to 8 hours following spinal anesthesia
Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Up to 8 hours following spinal anesthesia
Maximum sensory block level
Zeitfenster: Up to 30 minutes following spinal anesthesia
Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).
Up to 30 minutes following spinal anesthesia
Time to maximum sensory block level
Zeitfenster: Up to 30 minutes following spinal anesthesia
Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).
Up to 30 minutes following spinal anesthesia
Need for additional anesthetic procedure
Zeitfenster: From spinal anesthesia to the end of surgery
Whether an additional anesthetic procedure was required during surgery, including sedation or conversion to general anesthesia
From spinal anesthesia to the end of surgery
Time to regression of sensory block by two dermatomes (cold test)
Zeitfenster: Up to 2 hours following spinal anesthesia
Time (in minutes) from spinal puncture to two dermatome sensory regression assessed by a standardized cold test
Up to 2 hours following spinal anesthesia
Incidence of hypotension
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of hypotension, defined as a systolic blood pressure (SBP) < 90 mmHg and/or a mean arterial pressure (MAP) < 65 mmHg and/or a decrease in blood pressure ≥ 30% from baseline
From spinal anesthesia to 24 hours after surgery
Incidence of bradycardia
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of bradycardia defined as a heart rate (HR) < 50 bpm
From spinal anesthesia to 24 hours after surgery
Incidence of nausea
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of nausea reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of vomiting
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of vomiting reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of pruritus
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of pruritus reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Incidence of urinary retention
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of urinary retention reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery
Maximal pain score in the PACU
Zeitfenster: Up to 6 hours following spinal anesthesia
Maximal pain score collected in the PACU using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain).
Up to 6 hours following spinal anesthesia
Total opioid consumption
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Total opioid consumption, converted to oral morphine equivalents (OME, mg) from the intraoperative period to 24 hours postoperatively, including opioid use at home as reported during the Day 1 follow-up
From spinal anesthesia to 24 hours after surgery
Pain intensity
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Pain intensity at rest and during movement will be assessed using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain). Pain scores will be recorded intraoperatively (H0)in the PACU (H1), during ambulatory hospitalization (H3 and H6), and at home until Day-1 (H9, H12 and H24).
From spinal anesthesia to 24 hours after surgery
Duration of surgery
Zeitfenster: Intraoperative period
Time (in minutes) between the skin incision and the last suture
Intraoperative period
Incidence of post-puncture headache
Zeitfenster: From spinal anesthesia to 24 hours after surgery
Any episode of headache reported by the patient or nursing team
From spinal anesthesia to 24 hours after surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. September 2026

Primärer Abschluss (Geschätzt)

31. August 2028

Studienabschluss (Geschätzt)

1. September 2028

Studienanmeldedaten

Zuerst eingereicht

19. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Juni 2026

Zuerst gepostet (Tatsächlich)

29. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Sodium Chloride 0.9%

3
Abonnieren